Seager, R. J.
Senosain, Maria-Fernanda
Van Roey, Erik
Gao, Shuang
DePietro, Paul
Nesline, Mary K.
Dash, Durga Prasad
Zhang, Shengle
Ko, Heidi
Hastings, Stephanie B.
Strickland, Kyle C.
Previs, Rebecca A.
Jensen, Taylor J.
Eisenberg, Marcia
Caveney, Brian J.
Severson, Eric A.
Ramkissoon, Shakti
Conroy, Jeffrey M.
Pabla, Sarabjot http://orcid.org/0000-0002-7746-9144
Article History
Received: 30 October 2023
Accepted: 21 January 2024
First Online: 7 February 2024
Declarations
:
: Approval for this study was obtained from an independent institutional review board (IRB), the Western Copernicus Group (WCG) (ExternalRef removed), under protocol # 1340120. The WCG IRB determined this study met requirements for a waiver of informed consent under 45 CFR 46 116(f)(2018 Requirements) and 45 CFR 46.116(d) (Pre-2018 Requirements).
: Not applicable.
: RJS, MFS, EVR, SG, PD, MKN, DPD, SZ, JMC, and SP are employees of OmniSeq (Labcorp Oncology), a division of Labcorp. HK, SBH, KCS, RAP, TJJ, EAS, and SR are employees of Labcorp Oncology, a division of Labcorp. ME and BJC are employees of Labcorp. RJS, EVR, SG, SP, and JMC are listed as authors on a pending patent entitled Methods and systems for analyzing and utilizing cancer testis antigen burden.